Dr George Muchnicki

​Dr Muchnicki graduated in medicine from Monash University and was in private practice for 25 years. For the last 14 years he has been involved in funding and commercialising R&D in the biotechnology sector.

Dr Muchnicki is also currently interim Chairman & CEO of Genetic Technologies Limited (ASX: GTG), an ASX listed Biotech.

E: [email protected]
T:  +61 415 634 468
E:  [email protected]
Level 1, Suit 7
321 Chapel Street
Prahran, Victoria, 3181
​Australia
© COPYRIGHT 2022 L39 Capital | ABN 94 614 364 117
L39 Capital Pty Ltd (L39) ABN 94 614 364 117 is a Corporate Authorised Representative (CAR #1250323) of Primary Securities Ltd (Primary) ABN 96 089 812 635 AFSL 224107. Primary is the trustee of the L39 Capital fund. L39 is authorised to provide general advice only to wholesale investors. This website is for general informational purposed only and no person(s) circumstances, objectives or needs have been taken into account when preparing this information.